Tempus AI: Data And Applications Will Unlock More Upside

Tempus AI is viewed as a continued buy following a 60% rally, supported by 31% year-over-year growth in Q2 oncology testing volumes. MRD test volumes have nearly doubled since Q4 2025, supporting the strategic rationale for its Personalis acquisition. The data and applications segment grew 28% in Q2, with strong bookings and AI-driven product development underpinning longer-term growth and margin-expansion expectations.

Analysis

The investable question is whether TEM can convert testing growth into a higher-quality, recurring data monetization stream rather than remain a volume-driven diagnostics company. If data and applications bookings are translating into multi-year pharma contracts, incremental gross margins should be materially above clinical testing margins, supporting both EBITDA inflection and a valuation premium versus diagnostic peers. The key diligence item is revenue recognition, contract duration, renewal rates, and customer concentration; bookings without evidence of conversion to recognized revenue should not be capitalized at a software-like multiple.

Competitive pressure is likely to intensify in MRD. Natera (NTRA) has the strongest established commercial position in tissue-informed MRD, while Guardant Health (GH) and Exact Sciences (EXAS) have incentives to bundle testing into broader oncology workflows. TEM's advantage is potentially its clinical-genomic dataset and workflow integration, but reimbursement coverage and physician adoption—not AI product announcements—will determine whether volume growth persists through the next 2-4 quarters.

After a 60% move, the near-term risk/reward is less attractive absent an upward revision to FY revenue or gross-margin guidance. The market may be underestimating integration, dilution, and reimbursement risk associated with the acquired MRD capability; conversely, it may be underestimating the operating leverage if data revenue becomes a larger mix of sales. A deceleration in testing volume growth below 20%, weak data-segment conversion, or rising sales-and-marketing expense as a percentage of revenue would falsify the bullish thesis over the next 1-3 quarters.

The contrarian view is that the rally may already discount a successful transition from diagnostics to healthcare-data platform before the economics are visible. TEM should outperform if it demonstrates that pharma/data revenue grows faster than testing while consolidated gross margin expands; otherwise, comparable diagnostics names offer less execution-sensitive exposure. This is a 6-18 month fundamental story, not a clean days-to-weeks momentum entry.

Key Decisions for Investors

• Do not chase TEM immediately after the rally; establish a 50% starter only on a 10-15% pullback or after the next earnings release confirms raised full-year revenue guidance and stable/improving gross-margin guidance. Target a 6-12 month holding period; exit if testing growth falls below 20% for two consecutive quarters.
• Use a relative-value structure: long TEM / short GH in equal dollar amounts over 6-9 months. The thesis is that TEM's data-platform optionality and oncology workflow integration can produce superior revenue mix and margin progression, while GH remains more exposed to reimbursement and commercialization costs. Cover the short if GH delivers a material reimbursement expansion or TEM's data bookings fail to convert into revenue.
• Monitor NTRA's MRD volume growth, payer coverage announcements, and pricing commentary as the most relevant competitive read-through. Accelerating NTRA growth alongside TEM's volume growth would suggest market expansion; NTRA share gains or TEM pricing concessions would weaken the TEM margin thesis.
• Before increasing exposure, verify the acquired MRD asset's purchase accounting, earn-out obligations, and contribution to organic versus acquired growth. If growth is predominantly inorganic or requires sustained elevated sales-and-marketing spend, treat TEM as a watch item rather than a core long.